Thymectomy + PDN Beneficial for Non-Thymomatous Myasthenia Gravis
For patients with non-thymomatous myasthenia gravis, thymectomy plus prednisone confers benefits versus prednisone alone at 5 years.
Myasthenia Gravis
Belimumab Nonsuperior to Placebo for Reducing Symptoms of Myasthenia Gravis
The investigators suggest that the recruited participants may have reached a plateau in symptoms, which may have decreased the chances of additional improvement with belimumab treatment.
Firdapse NDA Submitted for Lambert-Eaton Myasthenic Syndrome
Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.
Myasthenia Gravis Impairment Index Indicates Response to Prednisone, IVIg, PLEX
The Myasthenia Gravis Impairment Index was developed to incorporate patient input at different stages of disease progression.
Eculizumab Safe, Tolerable for Refractory Generalized Myasthenia Gravis
Treatment with eculizumab was associated with a significant benefit on quality of life.
FDA Approves Myasthenia Gravis Treatment
The FDA has approved Soliris for treating adults with myasthenia gravis.
Rituximab Improves Outcomes in Patients With Anti-MuSK Myasthenia Gravis
Patients with anti-muscle-specific kinase myasthenia gravis typically have a more severe disease presentation, with early bulbar, neck, and respiratory muscle weakness.
Alexion Seeking New Indication for Myasthenia Gravis Drug
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Rituximab Offers Hope for Refractory Myasthenia Gravis
Sixty-three percent of patients achieved a complete and stable response that allowed them to discontinue all immunotherapies.
Thymectomy Helps Improve Strength in Myasthenia Gravis
Patients who underwent surgery also experienced lower distress levels from treatment-related symptoms.
